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The burns treatment is difficult, uncomfortable for the patient, and expensive for health system. Due to antimicrobial properties of
silver nanoparticles (AgNP), these particles can avoid bacterial infection in wound and accelerate the wound healing. Furthermore,
the complexation of AgNP with enoxaparin (low molecular weight heparin) may improve the healing process of lesions due to
anti-inflammatory and angiogenic activity of enoxaparin (Enox). The aim of this study was evaluated the activity and toxicity of
biogenic AgNP and AgNP complexed with Enox in in vivo burn wound model. AgNP was produced by biosynthesis method using
Fusarium oxysporum. AgNP (20–40 nm) exhibited high stability due to protein capping around the particles that was confirmed by
TEM, fluorescence spectroscopy, and FTIR.The wound contraction in in vivomodel, after 28 days of treatment, was 55, 89, 91, and
95% for control, Enox, AgNP, and AgNP-Enox groups, respectively. No clear toxic effects in the biochemistry and hematological
parameters were verified in all treated groups.However, in theAgNP-Enox group, a statistically significant increase in the urea levels
was observed indicating increased proteolysis due to inflammation process.The results demonstrated that the complex AgNP-Enox
is interesting for wound healing decreasing the time of lesions healing.
1. Introduction
Millions of people worldwide are burned every year.The cur-
rent treatment of second and third degree burns is complex,
uncomfortable for the patient and costly to the health system.
Mortality fromburns is estimated at 5% to 8.4% and for burns
of over 30% of body surface is around 55% [1]. In the United
States, 7.5 billions of dollars by year is spent in treatment of
burnwound infections [2]. Further, the sequels of burns affect
the life quality and produce social and emotional impact
on patients [1]. However, the wound healing process is a
complex process that includes some phases: haemostasis,
inflammation, proliferation, pithelisation, maturation, and
remodelling of the scar tissue [3–5]. In these phases numer-
ous cell-signalling events are required for a wound efficient
repair [6]. Thus, products that improve or accelerate the
wound healing phases are interesting to burn treatment. An
example is the topical or parental application of heparin [7–
11]. Heparin and enoxaparin (low molecular weight heparin)
are used as anticoagulant in the thrombosis treatment [12].
Heparin had been studied to burn treatment in humans
and animals showing significant therapeutic results [13, 14].
This drug can be interesting to burn and ulcers treatment
because enoxaparin (Enox) exhibits anti-inflammatory effect,
reduces local pain, promotes angiogenesis and epithelial-
ization, restores the collagen, has anticoagulant activity,
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and accelerates the healing process indicating it to be an
interesting drug for burn treatment [9, 15, 16]. However, the
application of Enox can lead to bleeding, thrombocytopenia
and allergy effect [8]. Thus, for topical application of heparin
or Enox the positive and negative effects should be evaluated
and its systemic absorption needs to be avoided.
A great problem in the burn healing is the bacterial
contamination.This infection hinders the wound healing and
is responsible for 75% of all deaths in patients with burns
exceeding 40% of the total body surface area [17]. Gram-
positive bacteria such as Staphylococcus aureus gram-negative
bacteria like Escherichia coli and Pseudomonas aeruginosa
are common in burnt surfaces. The presence of bacteria,
mainly multiresistant organisms and bacterial biofilms, in
the wound burn delays the wound-healing process because
of competing with host cells for nutrients and oxygen.
Furthermore, their waste products are also toxic to host cells
[18, 19]. Thus, a product that improves the wound healing
and exhibits antibacterial properties can be more efficient
and interesting to burn treatment. In this way, silver ions
or silver nanoparticles are interesting to burn treatment due
to their high antimicrobial activity. Silver has been used
for a century due to its great antimicrobial activity against
bacteria, viruses, and fungi. Furthermore, the potential anti-
inflammatory effect of silver and its effects in accelerating
wound healing were recently shown [5, 6, 20–24]. Nowadays,
silver sulfadiazine is used in the burn treatment in order to
avoid the bacterial contamination. However, studies show
that this treatment is archaic and can increase the patient risk
to develop leucopenia, neutropenia, erythema multiforme,
crystalluria, andmethemoglobinemia. Furthermore, nephro-
and hepatic toxicity is commonly observed during the treat-
ment [25–27]. Thus, new formulations have been studied
such as silver nanoparticles. The antimicrobial activity of sil-
ver nanoparticles is higher than silver ions due to their small
size and high surface-to-volume ratio [17, 28]. Furthermore,
silver nanoparticles show lower ecotoxicity than silver ions
[29]. Thus, the amount and time of burn treatment can be
decreased when using silver nanoparticles; the environment
impact will also decrease. Besides the antimicrobial activity of
silver nanoparticles, these particles can accelerate the wound
healing by its anti-inflammatory activity and its effect in
cytokines modulation [6]. Wright et al. [30], in the studied
porcine model of wound healing, verified that wound dress-
ings with silver showed antibacterial activity and significantly
promoted wound healing with rapid neovascularisation and
suppression of metalloproteinases. Similarly, Tian et al. [6]
verified that silver nanoparticles applied topically in animal
burn model were able to avoid antibacterial contamination,
reduce wound inflammation, and modulate the fibrogenic
cytokines, contributing for the wound healing. Thus, wound
healing has been studied with chitosan membrane with silver
nanoparticles [31, 32], nanofibers with silver nanoparticles
[2], and gel with silver nanoparticles [6, 24], showing it to be
an interesting alternative for burn treatment. Furthermore,
silver ions and silver nanoparticles are used in several
products on the market (more than 200 products in the
world) and its use should be evaluated due to its toxic effect
[33–35]. In in vitro and in vivo assays it was observed that
silver ions and silver nanoparticles exhibit toxic effects [28].
This effect can be related with production of reactive oxygen
species (ROS) that can disrupt the mitochondrial respiratory
chain and stop the ATP synthesis, which in turn causes DNA
damage or the silver disrupting the cell membrane [36, 37].
Thus, the toxicity of silver nanoparticles and its penetration
in skin damaged need to be investigated before its application
in wound.Therefore, in this study, the activity and toxicity of
biogenic silver nanoparticles (AgNP) and AgNP complexed
with enoxaparin (Enox)were evaluated in in vivo third degree
burnwoundmodel. Biochemistry and hematological analysis
was carrying out to evaluate the toxic effect of formulations
and the silver amount in different organs was also analyzed.
The results showed that the complex AgNP-Enox accelerated
the wound healing indicating great advantages of this system
in burn treatment.
2. Methods
2.1. Silver Nanoparticles Production. F. oxysporum strain (551)
from ESALQ-USP, Genetic and Molecular Biology Labora-
tory, Piracicaba, SP, Brazil, was used. The fungal inoculates
were prepared in a malt extract 2% and yeast extract 0.5%
at 28∘C in Petri plates. For silver nanoparticles production,
approximately 10 g of F. oxysporum biomass was taken in a
conical flask containing 100mL of distilled water. The system
was kept at 28∘Cby 72 h and, afterwards, the aqueous solution
(fungal filtrated) was separated from biomass by filtration.
In this fungal filtrated AgNO
3
(10−2mol⋅L−1) was added
and kept for several hours at 28∘C [38, 39]. The particles
formation was followed by absorption measured in an UV-
Vis spectrophotometer (HP8542A) at 440 nm.
2.2. Particle Size and Zeta Potential. The average particle size
(number average size) and size distributionweremeasured by
photon correlation spectroscopy (PCS) (Nano ZS Zetasizer,
Malvern Instruments Corp.) at 25∘C in polystyrene cuvettes
with path lengths of 10mm. The particles size and particles
concentration were also measured by nanoparticle tracking
analysis (NTA) using the Nanosight LM after the dilution of
particles in water. The zeta potential was measured in capil-
lary cells with path lengths of 10mm, using theNanoZS Zeta-
sizer. Measurements were performed with silver nanoparticle
dispersion diluted with KCl solution (10−3mol⋅L−1).
2.3. Protein Characterization. The protein capping around
silver nanoparticles was characterized by fluorescence spec-
troscopy (Perkin Elmer, LS 55) and by Fourier transform
infrared spectroscopy (FTIR) (FTLA 2000). For fluorescence
analysis, silver nanoparticles dispersion was diluted with
deionized water (1 : 1). The excitation wavelength used was
280 nm that corresponds with the excitation wavelength of
tryptophan and tyrosine amino acid. The FTIR analysis
was made in ART mode after the lyophilization of silver
dispersion.
2.4. Transmission ElectronMicroscopy (TEM) Analysis. Silver
nanoparticles were characterized by transmission electron
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microscopy and elemental spectroscopy imaging (ESI) (Carl
Zeiss Libra, 120KeV). For the analysis, one drop of the
particle dispersion was deposited on carbon-coated par-
lodion films supported in 300mesh copper grids (TedPella).
Bright field images and the elemental distribution of silver
nanoparticles were carried out.
2.5. Antimicrobial Activity of Silver Nanoparticles. Antimi-
crobial activity of silver nanoparticles was investigated by
determining the minimum inhibitory concentration (MIC)
on standard stocks of Staphylococcus aureus (ATCC 29213)
and methicillin-resistant Staphylococcus aureus (BEC 9393).
MIC values were determined by a microdilution test in a
culture broth. A suspension of microorganisms containing
about 105 CFUmL−1 was added to each well. The plates were
incubated at 37∘C for 24 h. MIC was defined as the low-
est silver nanoparticles concentration that inhibited visible
growth after 24 h of incubation. A positive control (growth)
formed by a culture broth containing microorganisms and
a negative control (sterility) formed by a culture broth
without microorganisms were included for each test. Each
concentration was tested in triplicate.
2.6. Complexation of Biogenic Silver Nanoparticles with
Enoxaparin. For complexation of AgNP with Enox,
1mg⋅mL−1 of Enox (Clexane, 60mg/0.6mL) was added
into the AgNP dispersion (10−2mol⋅L−1) under magnetic
stirring.The systemwas kept protected of the light and under
magnetic agitation by 12 h [40].
2.7. In Vivo Activity and Toxicity Assay. Male Wistar rats,
from the CEMIB-UNICAMP, were used respecting the
Brazilian Law on Animal Experiments. The experimental
protocol was approved by the University Committee on
Animal Research at UNICAMP (process number 2311-1).
2.7.1. Thermal Injury Animals and Treatment. In this study,
Wistar rats (250–300 g) were maintained in individual cages
during the assay, with free access to food and water, under
controlled conditions (room temperature at 22 ± 2∘C; 12 hr
light/dark cycle). The thermal injury was performed in
agreement with Tian et al. [6]. Briefly, rats were anesthetized
with ketamine (40mg/kg) and xylazine (20mg/Kg) through
intraperitoneal route. Afterwards, the hair of animals dorsal
was shaved off and placed in an appropriately sized template
device such that the shaved area of the skin on the animals’
back was exposed.The template device was then lowered into
a hot water bath (90∘C) to immerse the exposed skin area
(4 cm2) in hot water for 10 seconds causing a third-degree
thermal injury. Then, the animals received a subcutaneous
injection of saline solution [41]. After the thermal injury,
4 treatments were used on the dorsal skin: free natrosol
gel (control group), gel with silver nanoparticles (AgNP)
(1.4mg/g of gel), gel with Enox (Enox) (1mg/g of gel), and
gel with AgNP-Enox (1.4mg of AgNP-1mg of Enox/g of
gel). All formulation was prepared with no-ionic gel natrosol
(hydroxyethylcellulose) (2%). All the animals received the
treatment twice a day.The animals were sacrificed in different
days (7th, 14th, 21th, and 28th day after the thermal injury). In
each day 6 animals each group was euthanized and its blood
and 5 different organs (skin, kidney, spleen, lung, and liver)
were collected. The wound contraction was macroscopically
monitored usingmeasurements of the diameter of the injured
area, in centimeters, with a caliper (Mitutoyo). The measure-
ments were done 24 hours after the burn induction (initial
wound area) and after 28 days after induction. Data of wound
size were expressed as percentage of the initial wound area.
2.7.2. Biochemistry and Hematological Analysis
(a) Biochemistry Parameters. To analyze the in vivo toxicity
of formulation, biochemistry parameters (Urea, creatinine,
aspartate aminotransferase (AST), and alanine aminotrans-
ferase (ALT)) were carrying out in blood serum using
commercial kits: Katal for urea, AST, ALT analysis, and
Laborlab for creatinine. All analyses were carried out in a
Bioplus biochemical analyzer (Celm SB-190) at 37∘C.
(b) Hematological Parameters. Hematological parameters
evaluated in this work were leukocyte, erythrocyte, and
platelet counts and hemoglobin and white cells concentra-
tion. All blood samples were analyzed in an autohematology
analyzer (Mindray, BC- 2300).The platelet was counted using
a Neubauer chamber.
(c) Histological Analysis. In the histological analysis, the
damaged skin of the animals was removed and immersed
in fixative solution (4% of phosphate-buffered paraformalde-
hyde) for 24 at room temperature. The specimens were then
washed under running tap water and processed for histo-
logical embedding in paraffin. Longitudinal sections (5𝜇m)
were serially cut with a manual microtome and stained with
hematoxylin-eosin (HE) for routine histology. The sections
were examined by convencional light microscopy using a
Leica FW 4500 B microscope.
(d) Inductively Coupled Plasma Optical Emission Spectroscopy
(ICP-OES). Silver concentration in different organs (blood,
skin, kidney, spleen, lung, and liver) was determined by
ICP-OES. Briefly, organs samples (400mg of organs) were
digested with concentrated HNO
3
and then 2mL of H
2
O
2
(30%) was added. The system was heated until boiling and
the digestion continued for approximately 3 h. After, 5mL of
deionized water was added and the sample was analyzed by
ICP-OES.
2.8. Statistical Analysis. Statistical analysis for the in vivo
assay was carried out using One-way ANOVA for multiple
comparisons. A post hoc test (Tukey) was employed for
determining a significance level of 𝑃 < 0.05.
3. Results and Discussion
3.1. Biogenic Silver Nanoparticles. Silver nanoparticles with
negative surface charge (−22mV) were produced in 28 hours
exhibiting a plasmon band at 450 nm (Figure 1(a)). The high
negative charge of particles increases its stability (more than
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Figure 1: (a) UV-Vis spectrum of silver nanoparticles dispersion, (b) TEM Bright field image of the biogenic silver nanoparticles.
1 year) due to repulsion between the particles that avoid
its aggregation. Homogeneous and spherical particles with
20–40 nm of size were observed by TEM (Figure 1(b)). The
protein capping around the silver nanoparticles was observed
by TEM-ESI as shown in Figure 2. The mapping of Ag atom
(intense bright white points) shown in Figure 2(b) confirms
that particles are formed by silver. Furthermore, themapping,
in the same region, of N and S atoms (clouds of white
regions) observed around the silver nanoparticles (intense
bright white points) can be attributed to protein of the fungus
(Figures 2(c) and 2(d)). Some authors, in the literature,
suggest that AgNP can bind to proteins of microorganisms
either through free amine groups or of cysteine residues of
the proteins [42, 43].
Fluorescence analysis also indicated the protein in the
particles dispersion. Figure 3 shows the fluorescence spec-
trum of fungal filtrated before the addition of AgNO
3
(Figure 3(a)) and after AgNP formation (Figure 3(b)). In
the fungal filtrated can be observed only one band at
375 nm related to tryptophan or tyrosine amino acid from
proteins secreted by the fungus. However, in the AgNP
dispersion three bands were observed at 360 nm, 421 nm, and
487 nm. The first one can be attributed to the tryptophan
or tyrosine amino acid from the fungal proteins. The blue
shift in the maximum fluorescence emission at wavelength
of tryptophan/tyrosine (375 to 360 nm) can be related to
the conformational changes of fungal proteins during its
binding with AgNP. This change indicates that the trypto-
phan/tyrosine surroundings were changed to a more polar
environment when complexed with AgNP [44, 45]. Other
two bands (421 and 487 nm) correspond to the metal-ligand
interactions, which, in this case, is interaction between Ag
and fungal proteins, confirming the protein capping around
silver nanoparticles, as well as being also observed by TEM.
Similar results were obtained by Fayaz et al. [46] with silver
nanoparticles produced by the fungus Trichoderma viride.
The presence of protein around the AgNP is very important
because it enhances the particles stability without addition of
surfactant in the preparation.
The presence of peptide linkage was verified by FTIR
(Figure 4). An intense and broad band at 3233 cm−1 was
observed in FTIR spectrum, which can be assigned to N–
H stretching frequency due to peptide linkages present in
the fungus proteins. Furthermore, bands at 2931, 1624, and
1535 cm−1 assigned to the amide-II band, which arose due to
carbonyl stretch and –N–H– stretch vibrations in the amide
linkages of the proteins. The bands at 1317 cm−1, 1060 cm−1,
and 1031 cm−1 can be assigned to C–N stretching which are
generally found in protein [42, 43].
3.2. Antibacterial Activity of Silver Nanoparticles. Theantimi-
crobial activity of AgNP against S. aureus and methicillin-
resistant S. aureus (MRSA) was evaluated. In this study, a
low AgNP concentration inhibited the growth of S. aureus
and S. aureus MRSA indicating a great antibacterial effect of
these particles.TheMIC valuewas 1.87𝜇g/mL of AgNP (2.2 ×
1010 particles/mL ) for both strains of S. aureus. This result is
relevant because several physiological properties of the burn
environment predispose to infection, that is, a major compli-
cation of burns [19].Themost common causes of burnwound
infections were bacteria, mainly Staphylococcus aureus and
methicillin-resistant Staphylococcus aureus (MRSA) [19, 45].
MRSA is an opportunistic bacterial pathogen that causes
symptoms ranging from minor skin lesions to sepsis [47].
Furthermore, MRSA colonization is associated with loss of
skin grafts and delayed wound healing in burn patients.Thus,
the presence of MRSA in a burn unit is a concern because
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Figure 2: (a) Bright field image of the silver nanoparticles, (b) ESI map for Ag atoms (intense bright white points), and (c) and (d) ESI map
for N and S atoms, respectively (clouds of white regions around of intense bright white points).
it can increase the morbidity and mortality, increased length
of stay, and increased cost of care of burn patients [48]. To
decrease these problems, antimicrobial agent, such as sodium
sulfadiazine or silver nitrate, is applied in the wound burn.
However, microorganisms resistant to topical antimicrobial
agents have been reported [49]. Thus, AgNP of this work is
an interesting formulation for burn treatment due to its high
antimicrobial activity (low MIC value: 1.87 𝜇g/mL) against S.
aureus andMRSA.
3.3. In Vivo Activity. Figure 5(a) is an example of burn-
induced damage on the skin tissue (immediately after the
burn-induction). After 28 days of treatment it was possible
to observed, macroscopically, the presence of wound healing
in Enox and AgNP-Enox groups (Figures 5(d) and 5(e), resp.)
compared to control group (Natrosal gel) (Figure 5(b)). In the
AgNP group a small wound can be observed (Figure 5(c)).
These observations are in agreement with wound contrac-
tions, 28 days after the burn, which were 55, 89, 91, and
95% for control, Enox, AgNP, and AgNP-Enox groups,
respectively. The date is indicating of advantage of Enox
complex with AgNP. Furthermore, no bleeding was observed
in the Enox or AgNP-Enox groups suggesting that the Enox
doses (1mg/g of gel) added to AgNP were adequate for this
application.
Overall microscopic analysis of HE-stained histological
sections obtained from the treatments revealed some qual-
itative differences in the skin architectural arrangement or
cellularity. In control group, granulation tissue in different
stages of development, rich in fibroblasts, which differentiate
between myofibroblasts, was observed. In AgNP group,
myofibroblasts were observed in earlier stage. Similar results
were observed by Liu et al. [22] in the wound treatment with
silver nanoparticles produced by chemical method. In the
Enox group there was granulation tissue in more advanced
stage of scar evolution, with highest myofibroblasts density.
Similar result was observed for AgNP-Enox group, however,
without inflammatory infiltrate predominance. Thus, the
AgNP-Enox group showed greater wound healing compared
with others groups (Figure 6).
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Figure 3: Fluorescence spectra: (a) fungal filtrated before AgNO
3
addition, (b) fungal filtrated after AgNO
3
addition.
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Figure 4: FTIR-ATR spectrum of silver nanoparticles.
3.4. In Vivo Toxicity. Different parameters were evaluated to
investigate formulations toxicity. This study is very impor-
tant since silver nanoparticles exhibit toxicity and are not
biodegradable.Thus, AgNP penetration in damaged skin and
accumulated in organs were evaluated. Figure 7 shows silver
nanoparticles concentration in different organs. The results
showed that the silver amount found in all organs (liver,
kidney, spleen, and lung), except for the skin,was significantly
lower in the group treated with AgNP-Enox compared to
group treated with AgNP. In the skin, until 7th day after
the burn, the silver amount found in the skin of animals
treated with AgNP-Enox was significantly higher than the
group treated with AgNP. These results demonstrated that
silver nanoparticles reached the bloodstream; however, the
complex of AgNP with Enox may be helping in the elimina-
tion of AgNP. In both formulations lowest silver amount was
found in the blood andhighest concentrationwas observed in
liver and spleen. In general, nanomaterials are accumulated in
these organs that are major organs of the reticuloendothelial
system (RES) that are responsible for phagocytosis of foreign
bodies. This nanostructure accumulation has already been
described in the literature for TiO
2
particles, gold, quantum
dots, silica, and silver nanoparticles administered by oral
and intravenous path [50–56] and others. Despite AgNP
presence in different organs, no clear toxicity was observed
in the parameters evaluated when the different groups were
compared to control group (natrosol gel). No statistical
significant difference (𝑃 < 0.05), in almost all hematological
and biochemical parameters, was observed in the Enox,
AgNP, and AgNP-Enox groups when compared to control
group (natrosol gel) (Tables 1 and 2). Furthermore, the
majority of parameters evaluated were within the reference
range [57], even though all the groups evaluated are burnt.
An increased trend of white cells was verified in Enox, AgNP,
and AgNP-Enox groups that can be related with cytokines
modulation as described by Tian et al. [6]. In the same groups
an increased trend in platelets was also observed indicating
that these formulations can be acting in platelet activation
mainly in the 7th day after the burn.These results can explain
the wound healing acceleration in the treated groups (Enox,
AgNP, and AgNP-Enox). Furthermore, according to Table 1,
the urea levels were significantly higher (𝑃 < 0.001) in the
AgNP-Enox group when compared with control (natrosol
gel), AgNP, and Enox groups, indicating increased proteolysis
due to inflammation process.
4. Conclusion
This study showed that AgNP and Enox accelerated the
wound healing and this acceleration was more pronounced
when AgNP was complexed with Enox. This association was
responsible for reducing the time required for the differen-
tiation of fibroblasts into hyperactive cells (myofibroblasts)
involved in the generation of contractile force in the wound
and reversed the inflammatory process more quickly when
compared to the standalone application. Furthermore, silver
amount found in liver, kidney, spleen, and lung was signif-
icantly lower in the group treated with AgNP-Enox when
compared to the group treated with AgNP indicating that
the complexation of AgNP with Enox may be helping in the
excretion of AgNP. No in vivo toxic effect was clearly verified
in all parameters evaluated in the treated groups (AgNP,
Enox, andAgNP-Enox).There were no significant differences
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Figure 5: (a) Wound healing condition immediately after burn injury, (b) control (after 28 days of burn wound), (c) AgNP (after 28 days of
burn wound), (d) Enox (after 28 days of burn wound), and (e) AgNP-Enox (after 28 days of burn wound).
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Figure 6: Longitudinal sections of dorsal skin after 21 days of thermal injury (HE 200x). (a) Contracture area with greater presence of
extracellular matrix. Note the intense cellularity and large number of miofibroblasts in rats treated with free natrosol gel (󳶳). (b) HE staining
afterAgNP treatment reveals increases in dermis vascularity and lower amount ofmiofibroblast, since the higher amountwas observed earlier.
(c) Contracture region after Enox treatment showing hematoxylin-stained cells, typical of fibroblasts in hyperactive state in the papillary
dermis (󳶳). (d) Treatment with AgNP-Enox showing a contracture area with reduced number of myofibroblasts and reduced leukocyte
migration (󳶳). Images of rats after 28 days of treatment were not shown because there were similar to the rats treated for 21 days.
in the levels of creatinine, aminotransferases (ALT and AST),
and the hematological parameters between the control and
all groups treated, despite the systemic penetration of AgNP.
However, urea levels in the AgNP-Enox groups, after 7 days
of burn injury, were significantly higher when compared
with the other groups, indicating increased proteolysis due
to inflammation process. Furthermore, a trend in stimulate
the platelets production was observed in the groups treated
with Enox, AgNP, and AgNP-Enox mainly in the 7th day
after the burn. The elimination of these particles from the
animals was, probably, by spleen and liver, where a higher
silver concentration was found. This work demonstrated
an interesting formulation to treatment of burns based on
biogenic silver nanoparticles complexedwith enoxaparin that
improved the wound healing and did not exhibited clearly in
vivo toxicity.
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Table 1: Biochemistry and hematological analysis of control group, AgNP group, Enox group, and AgNP-Enox group after 7 days of burn
injury.
Control Enox AgNP AgNP-Enox
Urea (mg/dL) 45.5 ± 6.91 45.2 ± 2.86 46.0 ± 5.79 55.0 ± 5.10∗
Creatinine (mg/dL) 0.45 ± 0.08 0.43 ± 0.01 0.47 ± 0.07 0.46 ± 0.03
ALT (U/L) 51.7 ± 9.45 45.2 ± 5.73 40.7 ± 5.86 47.4 ± 6.35
AST (U/L) 79.7 ± 9.51 77.7 ± 8.56 78.7 ± 10.31 68.4 ± 6.76
Red cells (cell/𝜇L) × 106 7.64 ± 0.833 7.83 ± 0.563 8.32 ± 0.470 8.04 ± 0.396
Platelet (cell/𝜇L) × 103 825 ± 10.25 1217 ± 15.67 1206 ± 13.65 956 ± 9.85
Hemoglobin (g/dL) 15.2 ± 1.92 13.3 ± 1.91 14.0 ± 1.32 14.2 ± 0.88
White cells (cell/𝜇L) × 103 3.80 ± 0.100 5.15 ± 0.636 6.50 ± 1.99 8.27 ± 1.67
Data are means ± SD, 𝑛 = 5 per group. ∗𝑃 ≤ 0.001 for AgNP-Enox versus control, Enox, and AgNP.
Table 2: Biochemistry and hematological analysis of control group, AgNP group, Enox group, and AgNP-Enox group after 28 days of burn
injury.
Control Enox AgNP AgNP-Enox
Urea (mg/dL) 37.6 ± 10.4 43.2 ± 5.06 50.0 ± 10.61 49.4 ± 6.65
Creatinine (mg/dL) 0.54 ± 0.04 0.49 ± 0.06 0.51 ± 0.04 0.51 ± 0.04
ALT (U/L) 34.0 ± 4.54 33.5 ± 4.20 38.5 ± 52.89 37.7 ± 4.72
AST (U/L) 60.4 ± 10.11 52.0 ± 5.77 70.7 ± 11.03 77.2 ± 13.89
Red cells (cell/𝜇L) × 106 8.00 ± 0.562 9.07 ± 0.595 8.23 ± 0.207 7.75 ± 0.110
Platelet (cell/𝜇L) × 103 829 ± 13.66 805 ± 12.4 853 ± 10.50 789 ± 11.42
Hemoglobin (g/dL) 14.0 ± 0.62 14.6 ± 1.11 15.2 ± 0.33 14.1 ± 0.16
White cells (cell/𝜇L) × 103 6.95 ± 1.01 8.22 ± 1.29 4.22 ± 0.932 5.30 ± 0.784
Data are means ± SD, 𝑛 = 5 per group.
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Figure 7: Silver concentration in different organs in the groups
treated with AgNP and AgNP-Enox (Ag-E). ∗
𝑃
≤ 0.001 for AgNP-
Enox versus AgNP, ∗∗
𝑃
≤ 0.01 for AgNP-Enox versus AgNP.
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